氯吡格雷、普拉格雷与替格瑞洛对急性冠脉综合征支架术后内皮功能、炎症指标及血小板功能的影响
随机、盲法、平行研究纳入90例接受支架治疗的急性冠脉综合征患者,比较氯吡格雷、普拉格雷与替格瑞洛对血流介导舒张(FMD)的影响。随访期普拉格雷的FMD优于氯吡格雷(均差2.13,95%CI 0.68-3.58,P=0.0047)与替格瑞洛(均差1.57,95%CI 0.31-2.83,P=0.0155),且该优势仅见于支架前2小时给药者;普拉格雷组IL-6与ADP诱导的血小板聚集反应亦更低。
要点
- 普拉格雷较氯吡格雷和替格瑞洛改善随访期内皮功能,但仅在支架前2小时给药者中体现。
- 普拉格雷组IL-6水平及ADP诱导的血小板聚集反应低于氯吡格雷与替格瑞洛组。
- 支架后氯吡格雷与替格瑞洛组FMD受损,普拉格雷组未见此现象。
核心结论
- 在急性冠脉综合征接受支架治疗的患者中,与替格瑞洛和氯吡格雷相比,普拉格雷治疗与内皮功能改善、更强血小板抑制及IL-6水平降低相关,这些均可能具有预后意义。
- 该效应在支架术后立即接受研究药物的患者中消失。
研究设计与样本
- 随机、盲法、平行研究,共纳入90例患者(年龄62 ± 9岁,男性81例,糖尿病22例,非ST段抬高型心肌梗死49例)。
- 主要终点为支架置入后内皮依赖性血流介导舒张(FMD)的变化。
- 各组间任何临床参数均无显著差异。
主要发现
- 支架前急性期,三种药物均改善FMD,组间无差异(P = 0.73)。
- 支架置入使氯吡格雷组和替格瑞洛组FMD受损(均P < 0.01),普拉格雷组未见受损。
- 随访期普拉格雷优于氯吡格雷(均差2.13,95%CI 0.68-3.58;P = 0.0047)和替格瑞洛(均差1.57,95%CI 0.31-2.83;P = 0.0155),但差异仅限于支架前2小时接受研究治疗的患者。
- 替格瑞洛未显著优于氯吡格雷(均差0.55,95%CI -0.73至1.82;P = 0.39)。
- 普拉格雷组血浆IL-6(分别P = 0.02和P = 0.01)及ADP诱导的血小板聚集反应(分别P = 0.002和P = 0.035)低于氯吡格雷组和替格瑞洛组。
临床怎么用
- 对于急性冠脉综合征行支架治疗的患者,若在支架前2小时给予普拉格雷,可能获得更好的内皮功能、更强血小板抑制及更低IL-6水平。
- 支架术后立即给药可能丢失普拉格雷上述效应,给药时机需予考虑。
局限性
- 样本量较小(共90例),各组样本有限。
- 内皮功能与炎症指标的改善是否转化为临床预后获益尚未在本研究中证实。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: In a randomized, parallel, blinded study, we investigate the impact of clopidogrel, prasugrel, or ticagrelor on peripheral endothelial function in patients undergoing stenting for an acute coronary syndrome. METHODS AND RESULTS: The primary endpoint of the study was the change in endothelium-dependent flow-mediated dilation (FMD) following stenting. A total of 90 patients (age 62 ± 9 years, 81 males, 22 diabetics, 49 non-ST elevation myocardial infarctions) were enrolled. There were no significant differences among groups in any clinical parameter. Acutely before stenting, all three drugs improved FMD without differences between groups (P = 0.73). Stenting blunted FMD in the clopidogrel and ticagrelor group (both P < 0.01), but not in the prasugrel group. During follow-up, prasugrel was superior to clopidogrel [mean difference 2.13, 95% confidence interval (CI) 0.68-3.58; P = 0.0047] and ticagrelor (mean difference 1.57, 95% CI 0.31-2.83; P = 0.0155), but this difference was limited to patients who received the study therapy 2 h before stenting. Ticagrelor was not significantly superior to clopidogrel (mean difference 0.55, 95% CI -0.73 to 1.82; P = 0.39). No significant differences were seen among groups for low-flow-mediated dilation. Plasma interleukin (IL)-6 (P = 0.02 and P = 0.01, respectively) and platelet aggregation reactivity in response to adenosine diphosphate (P = 0.002 and P = 0.035) were lower in the prasugrel compared to clopidogrel and ticagrelor group. CONCLUSION: As compared to ticagrelor and clopidogrel, therapy with prasugrel in patients undergoing stenting for an acute coronary syndrome is associated with improved endothelial function, stronger platelet inhibition, and reduced IL-6 levels, all of which may have prognostic implications. This effect was lost in patients who received the study medication immediately after stenting. EUDRACT-NO: 2011-005305-73.
引用
- Schnorbus B, Daiber A, Jurk K, et al. Effects of clopidogrel vs. prasugrel vs. ticagrelor on endothelial function, inflammatory parameters, and platelet function in patients with acute coronary syndrome undergoing coronary artery stenting: a randomized, blinded, parallel study. Eur Heart J. 2020. PMID: 31899473. doi:10.1093/eurheartj/ehz917
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。